- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
- Details
- Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November 2023....
|
- Details
- Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene firadenovec, a novel intravesical gene therapy, highlighting its efficacy and patient-friendly administration schedule. Dr. Tyson shares insights on the drug's mechanism, its clinical trial outcomes, and its o...
|
- Details
- Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA approval for nadofaragene, noting patient interest in new treatment options. Dr. Meeks outlines the challenges with current therapies, including dual chemotherapy and Pembrolizumab, and points to nadofaragene's potential...
|
- Details
- Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation pr...
|
- Details
- Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. With a focus on real-world application, they explore the si...
|
- Details
- Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials. With nadofaragene firadenovec's unique once-quarterly dosing schedule...
|
- Details
- Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...
|
- Details
- Siamak Daneshmand hosts Trinity Bivalacqua to discuss advancements in non-muscle invasive bladder cancer, particularly focusing on newly FDA-approved therapies. Dr. Bivalacqua highlights the excitement surrounding the approval of new treatments for BCG unresponsive bladder cancer, including pembrolizumab and nadofaragene (ADSTILADRIN). He explains the significance of these developments, particular...
|
